ISSN: 1859 - 2872
Comparison of clinical and histopathological features between tumor budding-absent (Bd0) and Low tumor budding (Bd1-4) groups in malignant colorectal polyps at pt1 stage
Main Article Content
Keywords
Abstract
Objective: To evaluate the association between clinicopathological features in pT1 malignant colorectal polyps without tumor budding (Bd0) and those with low-grade tumor budding (Bd1-4). Subject and method: A descriptive cross-sectional study was conducted on 90 cases of pT1 malignant colorectal polyps with tumor budding graded as low or absent, assessed on H&E slides according to the 2016 International Tumor Budding Consensus Conference (ITBCC) guidelines. Clinical, paraclinical, and histopathological features were compared between Bd0 and Bd1-4 groups. Result: Bd0 accounted for 57.8% of cases. There were no statistically significant differences in clinical or paraclinical features between the two groups. However, Bd0 cases showed a higher tendency for endoscopic treatment (63.93% vs. 36.07%, p=0.086). Histologically, the Bd0 group had a significantly higher proportion of well-differentiated carcinomas (grade 1) compared to the Bd1-4 group (84,35% vs 17,65%, p=0,026). Conclusion: Bd0 is associated with more favorable histological features and may serve as a favorable prognostic indicator in pT1 malignant colorectal polyps. Further large-scale studies with long-term follow-up are needed to clarify the clinical value of Bd0.
Article Details
References
2. Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C (2012) Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut. 61(10): 1439-1446. doi:10.1136/gutjnl-2011-300843
3. Shaukat A, Mongin SJ, Geisser MS et al (2013) Long-term mortality after screening for colorectal cancer. New England Journal of Medicine 369(12): 1106-1114. doi:10.1056/NEJMoa1300720
4. Kuo E, Wang K, Liu X (2020) A focused review on advances in risk stratification of malignant polyps. Gastroenterology Research 13(5): 163. doi: 10.14740/gr1329
5. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R (2012) Tumor budding in colorectal carcinoma: Time to take notice. Mod Pathol 25(10): 1315-1325. doi: 10.1038/modpathol.2012.94
6. Lugli A, Kirsch R, Ajioka Y et al (2017) Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 30(9): 1299-1311. doi:10.1038/modpathol.2017.46
7. Bosch SL, Teerenstra S, de Wilt JH, Cunningham C, Nagtegaal ID (2013) Predicting lymph node metastasis in pT1 colorectal cancer: A systematic review of risk factors providing rationale for therapy decisions. Endoscopy 45(10): 827-34. doi:10.1055/s-0033-1344238
8. Burgart LJC, William V, Jain, Dhanpat (2022) Protocol for the Examination of Resection Specimens From Patients With Primary Carcinoma of the Colon and Rectum.
9. Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals of oncology 26(2): 259-271. doi:10.1093/annonc/mdu450
10. Kawamura I, Ohe R, Suzuki K et al (2024) Neighboring macrophage-induced alteration in the phenotype of colorectal cancer cells in the tumor budding area. Cancer Cell International. 2024;24(1):107. doi:10.1186/s12935-024-03292-7
11. Amin M, Edge S, Byrd D (2017) AJCC cancer staging manual. 2017: 256-257.
12. Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P, Goldin R (2012) Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy. Surgical oncology 21(4): 316-323. doi:10.1016/j.suronc.2012.08.003
13. Zlobec I, Bächli M, Galuppini F et al (2021) Refining the ITBCC tumor budding scoring system with a “zero-budding” category in colorectal cancer. Virchows Archiv: 1-6. doi:10.1007/s00428-021-03090-w
14. Kamall GH, Ulusoy C, Nikolovski A, Kamall S (2023) Tumour budding–an additional prognostic factor in colorectal cancer survival. Polish Journal of Pathology 74(1). doi:10.5114/pjp.2023.127040
15. Ueno H, Mochizuki H, Hashiguchi Y et al (2004) Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127(2): 385-394. doi:10.1053/j.gastro.2004.04.022
16. Quirke P, Risio M, Lambert R, Von Karsa L, Vieth M (2011) Quality assurance in pathology in colorectal cancer screening and diagnosis European recommendations. Virchows Archiv 458(1): 1-19. doi:10.1007/s00428-010-0977-6
17. Secinti IE, Ozgur T, Gursoy D, Dede I (2022) Should a fourth category be added to the international tumor budding consensus conference tumor budding scoring system in colorectal adenocarcinomas? APMIS. 2022;130(9):560-567. doi:10.1111/apm.13253
Article Sidebar
